Form 4: Elanco Animal Health Exec Reports Stock Unit Transaction

Elanco Animal Health Inc. reports a transaction involving deferred stock units by President, CEO, and Director Jeffrey N. Simmons.

Summary

• Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc., reported a transaction on May 1, 2026.
• The transaction involved 125.5855 deferred stock units, which represent the right to receive one share of Company common stock or its cash equivalent.
• These deferred stock units are set to settle in cash or shares following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.
• Following this transaction, Mr. Simmons beneficially owns 24,164.1158 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine disclosure of executive stock unit transactions rather than a significant strategic or financial event.

Positives

• The transaction indicates continued participation and investment in the company by its CEO and Director.
• Deferred stock units often align executive compensation with long-term company performance and shareholder value.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions, providing transparency into insider holdings and activities within the animal health sector.

Stakeholder Impact

• Shareholders: The filing provides transparency into executive stock ownership, which can be a factor in investor confidence.
• Employees: Deferred stock units are part of executive compensation, influencing employee perception of executive alignment with company performance.

Key Dates

Keywords

Elanco Animal Health, ELAN, Form 4, Insider Trading, Stock Options, Deferred Stock Units, Executive Compensation, SEC Filing